8-K current report · filed Oct 28, 2026

Biogen (BIIB) 8-K Current Report: October 28, 2026

Item 2.02Item EX-99.1BIIB overview

Short answer

Biogen (BIIB) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Biogen reported third-quarter fiscal 2026 results for the period ended September 30, 2026.

Biogen 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Biogen reported third-quarter fiscal 2026 results for the period ended September 30, 2026
  • Full financial results and management commentary are contained in Exhibit 99.1, the accompanying press release

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $2.8B, up 11% year over year, signaling renewed growth led by the Growth Portfolio and Apellis products
  • Growth Portfolio revenue $1.26B, up 49%, now 63% of Core Pharmaceutical revenue
  • Non-GAAP EPS $2.62, burdened by $284M of acquired IPR&D, upfront and milestone expense
  • GAAP diluted EPS $(0.14), reflecting transaction-related charges and a $20.6M net loss
  • FY 2026 Non-GAAP EPS guidance raised to $12.20-$13.00, while net debt reached approximately $6.4B after Apellis-related financing

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Biogen 8-K filings

Get the next BIIB 8-K as it lands

Follow BIIB for push alerts, or ask the research agent what this filing means.